Root for the home tech

Houston Astros executive addresses innovations in sports from esports to health care

Technology is changing America's pastime, and the Houston Astros have the lead off. Photo by Dylan Buell/Getty Images

Over the past decade or so, sports franchises have seen a boom in technology integration. The fact of the matter is that both the teams and the players need to tap into tech to have a competitive advantage on the field — and especially when it comes to the business side of things.

"Technologically advanced companies want to do business with technologically advanced companies," says Matt Brand, senior vice president of corporate partnerships and special events at the Houston Astros. "Old cats like me need to realize you have to stay current or else you're just going to get passed up."

Brand was the subject of a live recording of HXTV — the video arm of Houston Exponential — at The Cannon. He addressed several trends in sports technology, and shared how the Astros are approaching each new hot technology.

The Astros are pretty ahead of the curve when it comes to technology, Brand says, and the trick is keeping a pulse on potential game-changing technology far in advance of implementation.

"The things that we're developing now in 2019 and 2020 are the thing that are going to help us in 2024 and 2025," Brand says.

The approach to technology in sports is changing as younger players enter the scene.

"This generation of players want all the technology they can get," Brand says. "They want what's going on up to the day."

From esports to sports betting sites, here's what the hometeam has on its radar, according to brand.

The evolution of pitching technology

One aspect of the game that's been greatly affected by technology is pitching. Brand says that pitching coach, Brent Strom, is better able to do his job nowadays that there's better quality video and monitoring technologies. Brand cited the transformations of former pitcher Charlie Morton and current pitcher Ryan Pressly. Both saw impressive transformations in their pitching ability thanks to Strom and his technology.

"Brent has the ability to take technology and blend it with the craft," Brand says.

The players as industrial machines

One way the franchise thinks about its players is as machines — in the least objectifying way, surely. But Brand compares baseball players to major, expensive oil and gas machines, and in heavy industry, it's very common for a company to drop $30 million or more on a machine. Of course the company would schedule preventative maintenance and service appointments to protect their investments.

"We've got players now who are high performance machines," Brand says, citing players like Justin Verlander. "We want to make sure we have the best technology and the best care around them."

From doctors and nutritionists to the latest and greatest technologies, implementing the best practices is a good way to protect your assets.

Wearables and sleep technology

Another trend within sports is tracking sleep using technology. Wearable devices to track sleep and health are widely used, says Brand, but the Astros weren't comfortable with the constant monitoring.

"They feel like it's an invasion of privacy," Brand says. They feel like the data would be used against them when it came time to negotiate their contracts.

But prioritizing sleep is crucial in a sport where players travel across the country playing 162 games a season. Brand says investing in the players' sleep equipment is something they make sure to do.

Esports

Brand says, somewhat controversial, that esports is pretty low on the franchise's priority list, and there's one reason for that: Money.

"A lot of these sports teams aren't profitable right now," Brand says, noting that he knows that will probably change over the years.

While the teams themselves might not be making money, the number of users of video games makes for a different avenue to revenue.

"The platforms are what we see as profitable," Brand says, explaining how he's seen brands like Nike advertise in gaming apps.

"There's definitely a pathway to profitability, but esports means different things to different people," he says.

Sports marketing and betting

Looking toward the future, Brand says he sees movement coming in marketing and betting within sports.

With mobile devices in the hands of most sports event goers, brands have access to authentic, engaging content.

"Everyone with a phone is a producer of content, and a lot of brands want that content," he says.

Sports betting technologies have seen profitable success in other United States markets that allow it.

"Betting is the next biggest thing in sports," Brand says. "All the major leagues are saddled up with big money there. In Texas, it's illegal still, but it's coming."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted